Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
about
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
P2860
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Clinically relevant doses of F ...... -cell reactivity and function.
@en
Clinically relevant doses of F ...... -cell reactivity and function.
@nl
type
label
Clinically relevant doses of F ...... -cell reactivity and function.
@en
Clinically relevant doses of F ...... -cell reactivity and function.
@nl
prefLabel
Clinically relevant doses of F ...... -cell reactivity and function.
@en
Clinically relevant doses of F ...... -cell reactivity and function.
@nl
P2093
P2860
P1433
P1476
Clinically relevant doses of F ...... T-cell reactivity and function
@en
P2093
Andreas Parkner
Berend Isermann
Burkhart Schraven
Christine Höding
Denise Wolleschak
Florian H Heidel
Florian Perner
Katrin Hebel
Marie-Christine Wagner
Marina C Pils
P2860
P356
10.3324/HAEMATOL.2014.104331
P577
2014-03-14T00:00:00Z